News Sentiment

ANIX sentiment intelligence

Anixa Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.40 Week of 17 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+11.1% over one week, +16.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Anixa Biosciences (ANIX) CEO buys 5,000 common shares

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 11.1% Price confirming higher
Trend fit Trend inactive 16.8% over four weeks
Fair value 6.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 25
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 7
PR Newswire 6
TradingView 4
GuruFocus 3
simplywall.st 3
Investing.com 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 12
Deals and strategy 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Investing.com South Africa Direct company coverage

Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com

Anixa Biosciences Inc. (NASDAQ:ANIX) shares fell 4% despite the company presenting positive Phase 1 clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy. The breast cancer vaccine, developed with Cleveland Clinic, met all major primary endpoints, gen

Tone
Negative 39/100
Event
Market update
Published
26 Jun 2026 15:11
Source
Investing.com South Africa
TradingView Direct company coverage

Enterprise value to EBIT forward of Anixa Biosciences, Inc. – NASDAQ:ANIX

The article focuses on the enterprise value to EBIT forward for Anixa Biosciences, Inc. (NASDAQ: ANIX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics in relation to its enterprise value and earnings before intere

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:11
Source
TradingView